Literature DB >> 23561823

Ultra-rapid screening for substance-use disorders: the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST-Lite).

Robert Ali1, Sonali Meena, Brian Eastwood, Ian Richards, John Marsden.   

Abstract

BACKGROUND: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST 3.0; index test) is a structured interview for alcohol, tobacco, cannabis, stimulants, sedatives and opioid use disorders in general medical settings. Perceived administration time deters routine use. This study releases a short-form: the ASSIST-Lite.
METHODS: Diagnostic accuracy study among 2082 adults recruited from general medical (70%) and specialist mental health/addiction treatment services (22%). Current DSM-IV substance dependence (MINI International Neuropsychiatric Interview) and moderate-severe tobacco dependence (Fagerstrom Nicotine Dependence Test) were reference standards. Exploratory factor and item-response theory models re-calibrated ordinal test items. Items for the ASSIST-Lite were selected by diagnostic accuracy evaluation (area under the receiver-operating characteristic [AUC] curve [≤0.7]), sensitivity, specificity, positive and negative predictive values [PVP, NVP], kappa, likelihood ratios [LR+, LR-], and clinical utility index [CU+, CU-]).
RESULTS: For each substance an item pair was selected (AUC [0.8-1.0], sensitivity [0.8-1.0], specificity [0.7-0.8], PVP [0.8-1.0], NVP [0.7-1.0], kappa [0.5-0.9], LR+ [2.5-5.9], LR- [0.0-0.2], CU+ [0.7-0.9], and CU- [0.5-0.8]). Gender, age and recruitment setting (specialist mental health versus general medical) did not moderate accuracy, with the exception of opioids (AUC <0.7, participants ≥59 years). Male opioid users had more severe substance involvement scores that females (differential item functioning analysis, P=0.00). There was no evidence of differential accuracy between countries (AUC range, 0.8-1.0).
CONCLUSION: The ASSIST-Lite is an ultra-rapid screener which has been optimised for general medical settings. Optionally, a criterion question can be added to capture hazardous drinking, and to capture use of another type of mood-altering substance. Crown
Copyright © 2013. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ASSIST-Lite; Alcohol, Smoking and Substance Involvement Screening Test; Alcohol, tobacco, cannabis, stimulant, sedative, opioid, substance use disorder; Screening; Substance dependence

Mesh:

Year:  2013        PMID: 23561823     DOI: 10.1016/j.drugalcdep.2013.03.001

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  31 in total

1.  Item banks for substance use from the Patient-Reported Outcomes Measurement Information System (PROMIS(®)): Severity of use and positive appeal of use.

Authors:  Paul A Pilkonis; Lan Yu; Nathan E Dodds; Kelly L Johnston; Suzanne M Lawrence; Thomas F Hilton; Dennis C Daley; Ashwin A Patkar; Dennis McCarty
Journal:  Drug Alcohol Depend       Date:  2015-09-21       Impact factor: 4.492

2.  Identifying substance misuse in primary care: TAPS Tool compared to the WHO ASSIST.

Authors:  R P Schwartz; J McNeely; L T Wu; G Sharma; A Wahle; C Cushing; C D Nordeck; A Sharma; K E O'Grady; J Gryczynski; S G Mitchell; R L Ali; J Marsden; G A Subramaniam
Journal:  J Subst Abuse Treat       Date:  2017-01-31

3.  Use of a single alcohol screening question to identify other drug use.

Authors:  Peter C Smith; Debbie M Cheng; Donald Allensworth-Davies; Michael R Winter; Richard Saitz
Journal:  Drug Alcohol Depend       Date:  2014-04-05       Impact factor: 4.492

Review 4.  Brief interventions for alcohol and other drug use.

Authors:  Craig Rodgers
Journal:  Aust Prescr       Date:  2018-08-01

5.  Validation of the TAPS-1: A Four-Item Screening Tool to Identify Unhealthy Substance Use in Primary Care.

Authors:  Jan Gryczynski; Jennifer McNeely; Li-Tzy Wu; Geetha A Subramaniam; Dace S Svikis; Lauretta A Cathers; Gaurav Sharma; Jacqueline King; Eve Jelstrom; Courtney D Nordeck; Anjalee Sharma; Shannon G Mitchell; Kevin E O'Grady; Robert P Schwartz
Journal:  J Gen Intern Med       Date:  2017-05-26       Impact factor: 5.128

6.  The concurrent validity of the Problem Oriented Screening Instrument for Teenagers (POSIT) substance use/abuse subscale in adolescent patients in an urban federally qualified health center.

Authors:  Sharon M Kelly; Kevin E O'Grady; Jan Gryczynski; Shannon Gwin Mitchell; Arethusa Kirk; Robert P Schwartz
Journal:  Subst Abus       Date:  2017-07-07       Impact factor: 3.716

7.  Feasibility and acceptability of an audio computer-assisted self-interview version of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in primary care patients.

Authors:  Suzanne E Spear; Michele Shedlin; Brian Gilberti; Maya Fiellin; Jennifer McNeely
Journal:  Subst Abus       Date:  2016 Apr-Jun       Impact factor: 3.716

8.  Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use/misuse (TAPS) tool.

Authors:  Li-Tzy Wu; Jennifer McNeely; Geetha A Subramaniam; Gaurav Sharma; Paul VanVeldhuisen; Robert P Schwartz
Journal:  Contemp Clin Trials       Date:  2016-07-19       Impact factor: 2.226

9.  Validation and performance of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) among adolescent primary care patients.

Authors:  Jan Gryczynski; Sharon M Kelly; Shannon Gwin Mitchell; Arethusa Kirk; Kevin E O'Grady; Robert P Schwartz
Journal:  Addiction       Date:  2014-11-20       Impact factor: 6.526

10.  Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients.

Authors:  Jennifer McNeely; Li-Tzy Wu; Geetha Subramaniam; Gaurav Sharma; Lauretta A Cathers; Dace Svikis; Luke Sleiter; Linnea Russell; Courtney Nordeck; Anjalee Sharma; Kevin E O'Grady; Leah B Bouk; Carol Cushing; Jacqueline King; Aimee Wahle; Robert P Schwartz
Journal:  Ann Intern Med       Date:  2016-09-06       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.